Sugi Predict

Sugi Predict / Compounds / SCHEMBL3047249

SCHEMBL3047249

SCHEMBL3047249

O=C(O)CNC(=O)c1ccc(S(=O)(=O)Nc2ccccc2Oc2ccc(Br)cc2Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CCR2 P41597 8/20 0.48
▸ CCR1 P32246 2/20 0.48
▸ PTGDR2 Q9Y5Y4 8/20 0.47
▸ PTGDR Q13258 3/20 0.47
▸ CYP1A2 P05177 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ CCR4 P51679 1/20 0.43
▸ CCR5 P51681 1/20 0.43
▸ KCNH2 Q12809 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3050361 0.90 CCR2 (0.55) CCR2CCR1PTGDR2PTGDRCYP1A2
SCHEMBL3047255 0.90 CCR2 (0.54) CCR2CCR1PTGDR2PTGDR
SCHEMBL3050630 0.88 PTGDR2 (0.44) CCR2CCR1PTGDR2PTGDRCYP3A4
SCHEMBL3049201 0.87 CCR2 (0.57) CCR2CCR1CYP1A2CYP3A4CYP2D6
SCHEMBL3281374 0.84 PTGDR (0.41) CCR2CCR1PTGDR2PTGDR
Hydrochloric Acid SCHEMBL3280801 0.84 HTR6 (0.40) CCR2CCR1PTGDR2PTGDR
SCHEMBL15104212 0.83 CCR2 (0.48) CCR2KCNH2
SCHEMBL15103821 0.83 PTGDR (0.40) CCR2CCR1PTGDR2PTGDR
SCHEMBL15103926 0.83 SMN1; SMN2 (0.52) CCR2CCR1PTGDR2PTGDR
SCHEMBL14686192 0.83 PTGDR (0.40) CCR2CCR1PTGDR2PTGDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025059562-A1 SUBSTITUTED AMINOPYRIDINE COMPOUNDS AND METHODS OF TREATING DISEASE USING SAME ATAVISTIK BIO, INC. (US) 2025-03-20 — — WO disclosed
WO-2024072178-A1 COMPOUND FOR TARGETED PROTEIN DEGRADATION, AND USE THEREOF (주)사이러스테라퓨틱스 2024-04-04 — — WO disclosed
US-20240067639-A1 SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS University of Florida Research Foundation, Incorporation (US) 2024-02-29 — — US disclosed
EP-4210703-A1 SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS Expansion Therapeutics, Inc. (US) 2023-07-19 — — EP disclosed
WO-2022055922-A1 SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS EXPANSION THERAPEUTICS, INC. (US) 2022-03-17 — — WO disclosed
EP-3245200-B1 2-(PYRAZIN-2-YLCARBONYLAMINOMETHYL)BENZIMIDAZOLIUM COMPOUNDS AS EPITHELIAL SODIUM CHANNEL INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2021-03-10 — — EP disclosed
EP-3022198-B1 NOVEL 5-SUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS BOEHRINGER INGELHEIM INT (DE) 2019-09-11 — — EP disclosed
US-9981954-B2 2-(pyrazin-2-ylcarbonylaminomethyl) benzimidazolium compounds as epithelial sodium channel inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-05-29 — — US disclosed
US-20180002314-A1 2-(PYRAZIN-2-YLCARBONYLAMINOMETHYL) BENZIMIDAZOLIUM COMPOUNDS AS EPITHELIAL SODIUM CHANNEL INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-01-04 — — US disclosed
EP-3022196-B1 NOVEL BENZIMIDAZOLIUM COMPOUNDS BOEHRINGER INGELHEIM INT (DE) 2017-09-06 — — EP disclosed
EP-2057116-A1 NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS Richter Gedeon NYRT (HU) 2009-05-13 — — EP disclosed
US-7531546-B2 Spiro-substituted pyrrolo[2,3-D]pyrimidines as cathepsin inhibitors NOVARTIS AG (CH) 2009-05-12 — — US disclosed
WO-2008068540-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2008-06-12 — — WO disclosed
WO-2008050167-A1 NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2008-05-02 — — WO disclosed
EP-1592426-B1 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2007-12-19 — — EP disclosed
US-20060258690-A1 Spiro-substituted pyrrologyrimidines NOVARTIS AG (CH) 2006-11-16 — — US disclosed
US-20060247251-A1 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof NOVARTIS AG (CH) 2006-11-02 — — US disclosed
EP-1601677-B1 SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES NOVARTIS AG (CH) 2006-06-28 — — EP disclosed
EP-1592426-A1 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF Novartis AG (CH) 2005-11-09 — — EP disclosed
WO-2004069256-A1 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2004-08-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247251-A1 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof DPYD, P2RY1, P2RY2 CCR2 269/4885CCR1 85/4885PTGDR2 152/4885
US-20240067639-A1 SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS FUS, SNRPE, RRBP1 CCR2 3405/4885CCR1 3079/4885PTGDR2 3975/4885
US-20180002314-A1 2-(PYRAZIN-2-YLCARBONYLAMINOMETHYL) BENZIMIDAZOLIUM COMPOUNDS AS EPITHELIAL SODIUM CHANNEL INHIBITORS SCNN1A, TRPV1, SCNN1B CCR2 2692/4885CCR1 1387/4885PTGDR2 1734/4885
US-20060258690-A1 Spiro-substituted pyrrologyrimidines CTSS, CTSK, CTSZ CCR2 592/4885CCR1 1331/4885PTGDR2 1406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.